MorphoSys AG buy matumba
Summary
This prediction ended on 17.12.12 with a price of €30.01. The BUY prediction by matumba finished with a performance of 15.92%. matumba has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | - | - | - | - |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
Comments by matumba for this prediction
In the thread Morphosys AG diskutieren
pipline treibt den wert der aktie
erstmals schwarze zahlen
langfristig gesehen ist das wachstum intakt
und erfolgversprechend
21 von 76 antikörperbasierende wirkstoffprogramme
sind in der klinischen entwicklung
kursanstieg im september/oktober lässt einiges erhoffen
zweiter anstieg durch positive nachrichten erwartet